Patients with high EGFR expression have a survival advantage when treated with cetuximab plus chemotherapy, living up to 12 months on average. In contrast, those with low EGFR expression show no difference in overall survival.
Combining radiotherapy with androgen deprivation therapy significantly improves overall survival for men with locally advanced prostate cancer. The study, published in The Lancet, found that patients receiving both treatments had a higher 7-year survival rate compared to those receiving ADT alone.
Research shows that repeated administrations of radionuclide therapy with 188Re-HEDP improve overall survival rates, reducing pain in prostate cancer patients with hormone-refractory bone metastases. The study found significant increases in post-treatment survival for patients receiving two or three therapies.
Patients aged 60-75 who received the mini-transplant experienced comparable survival rates across three age groups, with increased comorbidities and cancer aggressiveness affecting outcomes. The five-year survival rate was 35% for overall and 32% for disease-progression free
A new long-term study reveals that heart transplantation is a safe and effective therapy, with survival rates improving by over 20% since its introduction in 1980. The study found that younger patients have better outcomes, while age negatively impacts survival rates.
Researchers found that lung cancer patients with diabetes had higher survival rates, including 43% at 1-year and 28% without diabetes. The benefits were seen across different stages of disease, suggesting that diabetes may not be a reason to withhold standard treatment.
A study published in the Journal of the National Cancer Institute found that African-American patients with resected stage II and III colon cancer experienced poorer overall and recurrence-free survival compared to whites. The five-year relative survival rates for black and white colorectal cancer patients were 57% and 68%, respectively.
A study found that women with BRCA2 genetic mutations experienced significantly better overall survival rates (61") compared to those without the mutation (25"). Additionally, BRCA2-mutated patients demonstrated longer progression-free survival durations and higher primary chemotherapy sensitivity rates
A study by UCLA's Jonsson Comprehensive Cancer Center found that a combination of chemotherapy and Herceptin significantly increases survival in patients with HER-2 positive breast cancer. The regimen without Adriamycin was comparable to the standard therapy, reducing heart toxicity and acute side effects.
A new study published in Journal of Hospital Medicine found that discussing end-of-life care with physicians does not affect survival rates. Patients who have advance directives in their medical records also have similar survival rates as those without these discussions and documents.
A new trial suggests that zoledronic acid may extend survival in postmenopausal breast cancer patients by boosting disease-free survival rates. However, the drug's effects on younger women are less clear-cut, with some studies indicating a possible adverse impact on recurrence rates outside bone.
A University of Maryland study found that young women with early-stage breast cancer who undergo lumpectomy and radiation have similar survival rates as those who undergo mastectomy. The analysis of nearly 15,000 patients showed no difference in overall or breast cancer-specific survival between the two groups.
Researchers discovered a molecular mechanism allowing signals from target cells to support neuron survival. Activated protein Rac plays a crucial role in long-range signaling and retrograde transport of neuronal survival signals.
A study found that ICD patients are living longer, with an average of nine years after implantation. However, right ventricular pacing negatively affects survival rates, while cardiac resynchronization therapy (CRT) improves outcomes.
A European study found radioembolization to be a viable treatment option for liver cancer patients, with median overall survival near 13 months. The procedure improved survival rates across different tumor stages and in patients with few treatment options.
Researchers found that longer AI use was associated with increased heart disease and bone fractures, but lower rates of blood clots and womb cancer. Use of AIs for 2-3 years after initial treatment may explain the lack of overall survival benefit despite improved breast cancer recurrence
A study published by the University of Rochester found that happily married people are more than three times as likely to survive bypass surgery for 15 years compared to unmarried individuals. The study also found that marriage quality is crucial for women's survival, with satisfying unions increasing their survival rate almost fourfold.
A study published in CMAJ found that type of cardiac arrest and underlying medical condition predict long-term survival rate. Patients with pulseless electrical activity or asystolic arrest, longer resuscitation duration, and advanced age are at high risk of death.
A study analyzing results from multiple international clinical trials of beta-blocker drugs found significant differences in survival rates among patients treated in different regions. US patients showed a lower survival rate compared to patients outside the US, while other countries demonstrated more substantial reductions in mortality.
A new treatment protocol has been shown to dramatically increase the survival rate of patients with incompatible kidneys, doubling their chances of eight-year survival. The treatment involves removing problematic antibodies from a patient's blood prior to transplant and aims to replace them with low-dose IVIg, resulting in an 80.6% sur...
A new study published in Journal of the American Medical Association found that removing lymph nodes due to microscopic cancer cells has no impact on survival outcomes for women with early-stage breast cancer. The study, conducted by Cedars-Sinai Medical Center, challenged the common approach to treating early-stage breast cancer.
Patients with idiopathic pulmonary fibrosis (IPF) who treat gastroesophageal reflux disease (GERD) have longer survival rates than those who don't. Treatment for GER may help reduce microaspiration and scarring of lung tissue, leading to improved survival outcomes.
Recent studies have shown that bone marrow transplant survival has significantly increased for young, high-risk leukemia patients, particularly those without matched donors. The results are attributed to advances in treatment and donor selection.
A Phase III trial found that amrubicin significantly improved tumor shrinkage, symptom control, and progression-free survival compared to topotecan in lung cancer patients. Patients treated with amrubicin also reported better quality of life and fewer adverse events.
New treatment options, including stereotactic ablative radiotherapy, have led to significant improvements in the survival of elderly Dutch lung cancer patients. Median survival for NSCLC patients increased by nearly 8 months between 2003 and 2009.
The EURTAC Phase III study found that erlotinib nearly doubled progression-free survival compared to chemotherapy, with a better tolerability profile for Western patients with NSCLC and EGFR activating mutations. The response rate to erlotinib was 54.5%, significantly higher than the 10.5% response rate to chemotherapy.
Research found that high EGFR expression is a predictor of improved survival in advanced non-small cell lung cancer patients treated with cetuximab and chemotherapy. Patients with high tumor EGFR expression averaged 12 months of overall survival, compared to 9.6 months for those without high expression.
A study of 64,034 women found that those with heart problems, chronic lung disease, and diabetes had lower overall survival rates. Researchers conclude that managing both cancer and comorbidities is crucial for improving patient outcomes.
Brain cancer patients who exercise regularly live significantly longer than sedentary patients, with a median survival of 21.84 months compared to 13.03 months. The study provides evidence that exercise interventions may impact progression and survival beyond symptom relief.
A Phase I clinical trial found that the experimental vaccine ICT-107 targets six antigens found on glioblastoma cells and three on cancer stem cells, improving immune responses and progression-free survival rates in patients. The study also showed that targeting these antigens may be a viable strategy for treating glioblastoma.
A new study found that non-invasive liver tests can accurately predict the five-year survival rate of patients with chronic hepatitis C. Liver stiffness measurement and the FibroTest were shown to have high predictive values for overall survival and survival without liver-related death.
A study published in JAMA found that delays in starting adjuvant chemotherapy after colorectal cancer surgery are associated with poorer survival outcomes. The research suggests that clinicians should prioritize timely access to chemotherapy to improve patient outcomes.
Researchers found that the HSPPC-96 vaccine for recurrent glioblastoma (GBM) extended median survival to 11 months, compared to the current three to five month survival rate. The vaccine showed a favorable safety profile and evoked a significant innate immune response in patients.
The COIN trial found that standard chemotherapy with cetuximab does not improve progression-free survival or overall survival in patients with advanced colorectal cancer. However, taking treatment breaks without compromising survival improves quality of life for most patients.
Survival rates for wealthier patients with glioblastoma have improved since 2000, while those in poorer areas and older than 70 have remained stagnant. The addition of temozolomide to post-operative radiation therapy has been shown to improve overall survival in younger patients.
Researchers found that increasing CRP levels resulted in increasingly poor prognosis, with a five-year survival rate decreasing from 90% to 74% and deaths from breast cancer increasing from 11% to 20%. Elevated CRP at diagnosis remained predictive of overall survival rates even after excluding patients with suspected bacterial infections.
A new experimental vaccine made from frozen immune cells has shown promise in extending the survival of metastatic prostate cancer patients. The vaccine, APC8015F, was found to increase median survival by approximately 10 months compared to those not treated with it.
Researchers found Asian non-small cell lung cancer patients survived longer than Caucasians regardless of the number of chemotherapy drugs given, with improved survival rates after targeted therapies were introduced in the early 2000s.
Patients with mismatch repair defects have lower tumor recurrence rates, longer remissions, and improved overall and disease-free survival compared to those without the defects. The study suggests that these defects are associated with a reduced response to 5-FU therapy, particularly in patients with inherited defects.
Researchers at Mayo Clinic found that patients diagnosed with advanced prostate cancer can enjoy long-term survival and a significant cancer-free interval. The study showed an 80% survival rate for patients with locally advanced prostate cancer at 20 years after surgery.
A study by Massachusetts General Hospital found that mild obesity, measured by body mass index, was associated with longer survival rates among ALS patients. Patients who were mildly obese outlived those of normal weight, underweight, or even overweight.
A new predictive test developed from gene expression microarrays identified patients with a high probability of survival following chemotherapy for breast cancer. The test had a positive predictive value of 56 percent and showed significant association between predicted sensitivity to treatment and improved distant relapse-free survival.
Activation of CTNNB1 biomarker is associated with better survival rates among obese patients with colorectal cancer, while physical activity improves survival for those without CTNNB1 activation. The study suggests a possible interactive effect between tumor CTNNB1 signaling and energy balance status on tumor cell behavior.
A new study suggests that damage to surrounding tissue during chemoradiation for high-grade glioma may play a role in determining long-term outcome and overall survival. Patients who experienced fewer side effects lived 4 months longer compared to those who did not.
A Phase III study found that GOLFIG increased progression-free survival to 16.5 months, compared to 7.5 months with FOLFOX regimen. Researchers added gemcitabine and granulocyte-macrophage colony stimulating factor to boost immune system.
A study published at the AACR Annual Meeting found that women with ovarian cancer and BRCA2 mutations had improved survival rates compared to those with BRCA1 mutations or no mutations. The five-year survival rate for women with BRCA2 mutations was 61%, significantly higher than those without mutations (36%). Further research is needed...
A new study found thalidomide significantly increased two-year disease-free survival rate (65%) compared to placebo (33%). However, overall survival rates were comparable between treatment groups. This finding provides new hope for difficult-to-treat liver cancer patients.
A Canadian study published in CMAJ found that avalanche victims buried in Canada died significantly quicker than those buried in Switzerland. The study analyzed data from 301 Canadian and 946 Swiss records of completely buried avalanche victims between 1980 and 2005.
The current US kidney allocation system prioritizes wait time over post-transplant survival, leading to higher repeat transplantation rates. Researchers propose ranking kidneys by potential post-transplant survival and matching them with candidates who have the longest expected survival.
The phase 3 trial shows that zalutumumab treatment is associated with a long-term benefit in progression-free survival, with a 20% PFS rate at 6 months compared to 7.3% in the best supportive care group. However, overall survival was not significantly increased.
Researchers found that high levels of CYP24A1 enzyme can predict lung cancer survival, with patients having higher levels experiencing nearly half the survival rate as those with low levels. The study suggests using vitamin D to prevent or delay cancer recurrence after surgery.
Researchers developed a new CPR method that increases long-term survival rates with good brain function by 50 percent. The technique uses two devices to increase blood flow, nearly tripling the amount compared to standard CPR.
Researchers at Boston University School of Medicine found that patients with invasive T3 and T4 non-small lung cancer who received chemotherapy before surgery had a significantly improved survival rate. The study, published in the Journal of Thoracic and Cardiovascular Surgery, showed that median survival was greatest for those who rec...
A recent study by researchers at Rhode Island Hospital has found that the protein RIP1 plays a dual role in sepsis, promoting both cell death and survival. The study suggests that RIP1 is necessary for survival during septic injury, and its pro-survival trigger may hold key to developing new treatments for sepsis.
A study published in Blood demonstrates that newborn screening and early diagnosis of Severe Combined Immunodeficiency (SCID) can improve survival rates. Babies diagnosed at birth and receiving a hematopoietic stem cell transplant have significantly reduced infections and improved survival outcomes.
A study published in Hepatology found that HIV-infected patients with liver cancer have a higher risk of dropping off the transplantation wait list compared to HIV-negative patients. Despite this, overall survival and recurrence-free survival rates are not significantly affected following liver transplantation.
A new CPR technique has been shown to increase long-term survival after cardiac arrest, with a 53% improvement in survival rates compared to standard CPR. The active compression-decompression cardio-pulmonary resuscitation (CPR) method provides nearly three times more blood flow to the heart and brain.
Researchers found that SIK2 suppressed CREB-mediated gene expression after oxygen and glucose deprivation, increasing neuronal survival in mice lacking SIK2. The SIK2-TORC1-CREB signaling pathway may serve as a potential therapeutic target for promoting neuron survival.
A new three-drug regimen including docetaxel has been shown to significantly improve the long-term survival of patients with locally advanced head and neck cancer. The addition of docetaxel to a standard two-drug chemotherapy regimen reduced the likelihood of death by 26% over six years, according to results from the TAX 324 trial.
A recent study published in the New England Journal of Medicine found that losing the NFKBIA gene promotes glioblastoma multiforme growth and reduces survival. Restoring this gene may improve survival for certain patients with glioblastoma, as it inhibits tumor cell growth and increases sensitivity to chemotherapy.